Open AccessCoexistence of multiple myeloma and chronic myeloleukosis in one patient
Author(s) -
О.В. Рыбина,
Ю. А. Шавель,
А А Петренко,
М. В. Галайко,
М. С. Литвиненко,
В. Е. Егорков,
A. Gubkin
Publication year - 2020
Publication title -
gematologiâ i transfuziologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-3042
pISSN - 0234-5730
DOI - 10.35754/0234-5730-2020-65-4-501-513
Subject(s) - medicine , thalidomide , dasatinib , multiple myeloma , chronic myelogenous leukemia , imatinib , chemotherapy , imatinib mesylate , oncology , maintenance therapy , surgery , myeloid leukemia , leukemia
Intoduction . Multiple myeloma (MM) and chronic myelogenous leukaemia (CML) are two haematological malignancies developing through tumour transformation of lymphoid and myeloid progenitor cells, respectively, not sharing a common ancestry. Coexistence of the two diseases is extremely rare. Aim . Clinical description of a patient diagnosed with CML in a few months after start of MM therapy. Main ndings . We report a clinical case of MM and CML in a 62 years-old female patient. MM was diagnosed newly and followed by 5 VD chemotherapy cycles. Treatment discontinued due to severe polyneuropathy. The patient was transferred to thalidomide maintenance therapy. CML was diagnosed 12 months after initiation of thalidomide therapy: BCR-ABL (p190), BCR-ABL (p210). Since imatinib produced short-term effect, dasatinib therapy was started. Following 16 months after the onset of dasatinib therapy, MM relapse and CML progression were diagnosed.